Experiences of levosimendan as an inotropic agent in conjunction with passive containment surgery

Scandinavian Cardiovascular Journal

Volumn 41, Issue 3, 2007, Pages 197-200

  Bredin, Fredrik ^a   Franco Cereceda, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiomyopathy; Heart failure surgery; Hemodynamics

Indexed keywords

ADRENALIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINAMIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM SENSITIZER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INOTROPIC AGENT; ISOPRENALINE; LEVOSIMENDAN; MILRINONE; NORADRENALIN; OXYGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; EXTRACORPOREAL CIRCULATION; FEMALE; FORWARD HEART FAILURE; HEART ASSIST DEVICE; HEART INDEX; HEART OUTPUT; HEART SURGERY; HUMAN; INTENSIVE CARE UNIT; MALE; OPEN HEART SURGERY; OXYGEN CONSUMPTION; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL;

ADULT; AGED; BLOOD PRESSURE; CARDIAC OUTPUT; CARDIAC SURGICAL PROCEDURES; CARDIOMYOPATHY, DILATED; CARDIOTONIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART RATE; HEART-ASSIST DEVICES; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; PYRIDAZINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34249008201     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.1080/14017430601137160     Document Type: Article

References (10)

1. Hunt, S. (2004) Heart failure overview. J Thorac Cardiovasc Surg., 127, pp. 1245-1246.
2. Konstam, MA, Udelson, JE, Anand, IS and Conn, JN. (2003) Ventricular remodeling in heart failure: A credible surrogate endpoint. J Card Fail., 9, pp. 350-353.
3. McKenzie, DB and Cowley, AJ. (2003) Drug therapy in chronic heart failure. Postgrad Med J., 79, pp. 634-642.
4. Figgitt, DP, Gillies, PS and Goa, KL. (2001) Levosimendan. Drugs., 61, pp. 613-627.
5. Franco-Cereceda, A., Lockowandt, U. and Olsson, A. (2004) Early results with cardiac support device implant in patients with ischemic and non-ischemic cardiomyopathy. Scand Cardiovasc J., 38, pp. 159-163.
6. Lehtonen, LA, Antila, S. and Pentikäinen, PJ. (2004) Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet., 43, pp. 187-203.
7. Nijhawan, N., Nicolosi, AC and Mongomery, MW (1999) Levosimendan enhances cardiac perfomance after cardiopulmonary bypass: A prospective, randomised placebo-controlled trial. J Cardiovasc Pharmacol., 34, pp. 219-228.
8. Lehman, A., Lang, J., Boldt, J., Isgro, F. and Kiessling, AH. (2004) Levosimendan in patients with cardiogenic shock undergoing surgical revascularization. A case series. Med Sci Monit., 10, pp. 89-93.
9. Muller, M., Junger, A. and Bräu, M. (2002) Incidence and risk calculation of inotropic support in patients undergoing cardiac surgery with cardiopulmonary bypass using an automated anesthesia record-keeping system. Br J Anaesth., 89, pp. 398-404.
10. McKinlay, KH, Schinderle, DB and Swaminathan, M. (2004) Predictors of inotrope use during separation from cardiopulmonary bypass. J Cardiothorac Vasc Anesth., 18, pp. 404-408.